Stockscreener 앱 받기
137.00
6.81%
-10.01
시간 외 거래:
135.80
-1.20
-0.88%
전일 마감가:
$147.01
열려 있는:
$142.81
하루 거래량:
1.79M
Relative Volume:
1.58
시가총액:
$7.73B
수익:
$763.34M
순이익/손실:
$51.40M
주가수익비율:
150.81
EPS:
0.9084
순현금흐름:
$104.46M
1주 성능:
+8.24%
1개월 성능:
+10.53%
6개월 성능:
-17.34%
1년 성능:
+10.88%
1일 변동 폭
$135.72
$144.72
1주일 범위
$124.85
$149.05
52주 변동 폭
$100.99
$175.77
Repligen Corp Stock (RGEN) Company Profile
명칭
Repligen Corp
전화
(781) 449-9560
주소
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, MDLN, ALC, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
137.00 | 8.29B | 763.34M | 51.40M | 104.46M | 0.9084 |
ISRG
Intuitive Surgical Inc
|
405.97 | 143.33B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
155.19 | 42.96B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
39.61 | 32.87B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
67.61 | 33.07B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
198.43 | 29.05B | 5.54B | 1.52B | 1.74B | 10.37 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-01 | 개시 | HSBC Securities | Buy |
| 2025-09-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-22 | 재개 | Stephens | Overweight |
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-29 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | Evercore ISI | In-line |
| 2025-02-10 | 개시 | TD Cowen | Buy |
| 2024-12-17 | 개시 | Canaccord Genuity | Hold |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-06-18 | 개시 | Guggenheim | Neutral |
| 2023-12-04 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-07-20 | 개시 | Wells Fargo | Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-03-28 | 개시 | The Benchmark Company | Buy |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | 개시 | UBS | Buy |
| 2021-10-14 | 개시 | Exane BNP Paribas | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-11-01 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | 개시 | SVB Leerink | Outperform |
| 2019-08-28 | 재확인 | First Analysis Sec | Outperform |
| 2019-08-23 | 재개 | Stephens | Overweight |
| 2019-07-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | 업그레이드 | CL King | Neutral → Buy |
| 2018-11-12 | 다운그레이드 | CL King | Buy → Neutral |
| 2018-09-26 | 개시 | H.C. Wainwright | Neutral |
| 2017-12-08 | 개시 | Citigroup | Buy |
| 2017-12-05 | 개시 | JP Morgan | Overweight |
| 2017-11-13 | 개시 | CL King | Buy |
| 2017-10-02 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | 개시 | William Blair | Outperform |
| 2017-02-13 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
Repligen Corp 주식(RGEN)의 최신 뉴스
A Look at Repligen Corp (RGEN) After 6.8% Decline -- GF Value $1 - GuruFocus
Insider Sell: Jason Garland Sells Shares of Repligen Corp (RGEN) - GuruFocus
Biolife Is Said to Have Drawn Takeover Interest From Repligen - Bloomberg.com
Repligen (RGEN) CFO completes 733-share Rule 10b5-1 stock sale - Stock Titan
A Look at Repligen Corp (RGEN) After 4.9% Gain -- GF Value $175. - GuruFocus
Stock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition Offer - The Motley Fool
Form 144 REPLIGEN CORP For: 25 June By Investing.com - Investing.com Australia
[144] REPLIGEN CORP SEC Filing - Stock Titan
Repligen jumps as investors revisit strong Q1 results and bioprocessing recovery outlook - Quiver Quantitative
Repligen Corporation (RGEN) Dropped Following the Earnings Release - Insider Monkey
Repligen Corp (RGEN) Shares Fall 4.1% -- What GF Score of 83 Tel - GuruFocus
Repligen Corp (RGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Repligen StockLong-term strategy and bioprocessing niche - AD HOC NEWS
Repligen Corporation (RGEN) Slid on Softened Enthusiasm for Life Sciences Tools - Insider Monkey
RGEN Technical Analysis & Stock Price Forecast - Intellectia AI
Repligen Corp (RGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Repligen Corp (RGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Repligen Corp (RGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Repligen Corp (RGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Repligen Corp (RGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Repligen Corp (RGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Repligen Corp (RGEN) Institutional Confidence - TradingKey
Repligen Corp (RGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MFS Mid Cap Growth Series's Repligen Corp(RGEN) Holding History - GuruFocus
RBC Capital Resumes Repligen Corp (RGEN) Stock Coverage. Here’s Its View - Insider Monkey
Billionaire Lee Ainslie’s 5 Stocks with Huge Upside Potential - Insider Monkey
Repligen Corp. Hits Day High with 8.45% Surge in Stock Price - Markets Mojo
Multi Cap Equity Fund's Repligen Corp(RGEN) Holding History - GuruFocus
Repligen Corp (RGEN) Shares Surge 3.8% -- What GF Score of 83 Te - GuruFocus
Repligen Corp (RGEN) Shares Surge 4.0% -- What GF Score of 79 Te - GuruFocus
Repligen (RGEN) down 3.2% since last earnings report: Can it rebound? - MSN
Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
State Street Small-Cap Equity V.I.S. Fund's Repligen Corp(RGEN) Holding History - GuruFocus
Repligen Corp at William Blair Growth Stock Conference Transcript - GuruFocus
RGEN Assumed by Wolfe Research -- Rating Upgraded to Outperform - GuruFocus
Wolfe Research initiates Repligen stock coverage with outperform rating By Investing.com - Investing.com Australia
Wolfe Research initiates Repligen stock coverage with outperform rating - Investing.com
Repligen Has A Cleaner Recovery Angle, But With High Valuation - Seeking Alpha
Repligen Corp stock (US7607591002): RGEN jumps after strong Nasdaq session - AD HOC NEWS
Repligen Corp (RGEN) Stock Up 8.4% and Still Undervalued -- GF S - GuruFocus
RGENRepligen Corp Stock Price and Quote - Finviz
Repligen's $833 Million Guide: Can Analytics And China Power The Next Leg? - Smartkarma
Repligen Jumps 12% This Week as June Investor Update Approaches - Bez Kabli
Repligen (RGEN) Edges Higher Amid Bioprocessing Sector OptimismFibonacci Arc - The Legal Advocate
Hear Repligen's CEO give company overview at June 3 webcast - Stock Titan
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference - Yahoo Finance
Repligen Corp stock (US7607591002): ESG progress and growth focus draw fresh attention - AD HOC NEWS
InvestingPro’s Fair Value model predicted Repligen’s 45% decline By Investing.com - Investing.com Canada
Q1 Rundown: Repligen (NASDAQ:RGEN) Vs Other Drug Development Inputs & Services Stocks - Yahoo Finance
Repligen’s 2025 Sustainability Report Highlights Carbon Emission Reductions and ESG Progress - geneonline.com
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report - Yahoo Finance
Repligen Corp (RGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.09%
0.52%
자본화:
|
볼륨(24시간):